Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $90.00 price target on the stock.
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 [Yahoo! Finance]
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Q32 Bio to Participate in Upcoming September Investor Conferences